PACT Funding News – Aclaris Therapeutics

Aclaris Therapeutics Inc., a Malvern, Penn.-based developer of dermatological therapeutics, has set its IPO terms to 5 million shares being offered at between $14 and $16 per share. It would have an initial market cap of around $291 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol ACRS, with Jefferies and Citigroup serving as lead underwriters. Aclaris has raised $31.5 million in VC funding from Vivo Ventures (31.2% pre-IPO stake), Fidelity Biosciences (28.5%) and Sofinova Ventures (12%). www.aclaristx.comĀ 


©2016 PACT All Rights Reserved